1. Home
  2. GLUE vs PWOD Comparison

GLUE vs PWOD Comparison

Compare GLUE & PWOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • PWOD
  • Stock Information
  • Founded
  • GLUE 2019
  • PWOD 1934
  • Country
  • GLUE United States
  • PWOD United States
  • Employees
  • GLUE N/A
  • PWOD N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • PWOD Major Banks
  • Sector
  • GLUE Health Care
  • PWOD Finance
  • Exchange
  • GLUE Nasdaq
  • PWOD Nasdaq
  • Market Cap
  • GLUE 283.6M
  • PWOD 231.2M
  • IPO Year
  • GLUE 2021
  • PWOD N/A
  • Fundamental
  • Price
  • GLUE $5.20
  • PWOD $32.02
  • Analyst Decision
  • GLUE Buy
  • PWOD
  • Analyst Count
  • GLUE 2
  • PWOD 0
  • Target Price
  • GLUE $13.50
  • PWOD N/A
  • AVG Volume (30 Days)
  • GLUE 415.2K
  • PWOD 74.8K
  • Earning Date
  • GLUE 08-07-2025
  • PWOD 07-24-2025
  • Dividend Yield
  • GLUE N/A
  • PWOD 4.00%
  • EPS Growth
  • GLUE N/A
  • PWOD 28.19
  • EPS
  • GLUE 0.08
  • PWOD 2.80
  • Revenue
  • GLUE $159,487,000.00
  • PWOD $74,314,000.00
  • Revenue This Year
  • GLUE $49.02
  • PWOD N/A
  • Revenue Next Year
  • GLUE N/A
  • PWOD N/A
  • P/E Ratio
  • GLUE $66.53
  • PWOD $11.55
  • Revenue Growth
  • GLUE 14889.38
  • PWOD 16.68
  • 52 Week Low
  • GLUE $3.50
  • PWOD $20.18
  • 52 Week High
  • GLUE $12.40
  • PWOD $34.56
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 64.63
  • PWOD 69.96
  • Support Level
  • GLUE $4.42
  • PWOD $29.61
  • Resistance Level
  • GLUE $4.85
  • PWOD $32.51
  • Average True Range (ATR)
  • GLUE 0.24
  • PWOD 0.60
  • MACD
  • GLUE 0.05
  • PWOD 0.24
  • Stochastic Oscillator
  • GLUE 81.55
  • PWOD 87.96

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About PWOD Penns Woods Bancorp Inc.

Penns Woods Bancorp Inc is the bank holding company for Jersey Shore State Bank and Luzerne Bank. The banks serve customers in North Central and North Eastern Pennsylvania through their retail banking, commercial banking, mortgage services and financial services divisions. The Banks are engaged in commercial and retail banking which includes the acceptance of time, savings, and demand deposits, the funding of commercial, consumer, and mortgage loans, and safe deposit services. Utilizing a branch office network, ATMs, Internet, and telephone banking delivery channels, the Banks deliver their products and services to the communities residing in.

Share on Social Networks: